



# Human Anti-Certolizumab pegol monoclonal antibody, clone AbD34136ia (CABT-ZB1165)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Specificity</b>	Certolizumab pegol
<b>Target</b>	Certolizumab pegol
<b>Immunogen</b>	Certolizumab pegol
<b>Isotype</b>	IgG1, κ
<b>Source/Host</b>	Human
<b>Species Reactivity</b>	N/A
<b>Clone</b>	AbD34136ia
<b>Affinity Constant</b>	The monovalent intrinsic affinity of AbD34136ia was measured as $K_D = 3$ nM by real time, label free molecular interaction analysis on immobilized certolizumab pegol.
<b>Purification</b>	Protein A purified
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	Suitable for use in ADA bridging ELISA. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.
<b>Format</b>	Liquid
<b>Concentration</b>	Lot specific
<b>Size</b>	100 µg

<b>Buffer</b>	PBS
<b>Preservative</b>	0.01% Thiomersal
<b>Storage</b>	Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
<b>Ship</b>	Wet ice

## BACKGROUND

<b>Introduction</b>	Certolizumab pegol (Cimzia) is a humanized Fab fragment antibody (50 kDa), covalently bound to two polyethylene glycol (PEG) chains (PEG2MAL, 40 kDa) via a thioether linkage; total molecular weight 90.8 kDa. PEG helps to delay the metabolism and elimination of the drug. The removal of the Fc region increases the half-life of the drug and prevents complement fixation and antibody-mediated cytotoxicity. The drug is approved for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It binds to free and membrane-bound human TNF $\alpha$ and neutralizes its activity by inhibiting the binding of TNF $\alpha$ to human p55 and p75 TNF receptors.
<b>Keywords</b>	Certolizumab pegol, Cimzia